natalizumab vs Tyruko (natalizumab-sztn)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: α4 integrin · full Multiple Sclerosis pipeline
natalizumab · Tysabri
Marketed by Biogen
NCT00027300 · Phase 3 · completed
The trial was large, randomized, blinded, and placebo-controlled, with hard clinical endpoints of relapse rate and disability progression, and natalizumab significantly reduced both (68% relapse-rate reduction and 42% reduction in sustained disability progression, both P<0.001).
Next expected readout: October 2027 · NCT05418010 (registry estimate)
Reported efficacy
The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years. (1 year and 2 years): Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001). (met)
Result source: NCT00027300
Tyruko (natalizumab-sztn)
Marketed by Sandoz Group AG and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT05418010 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | natalizumab | Tyruko (natalizumab-sztn) |
|---|---|---|
| Annualised relapse rate | 0.5 vs 1.7−1.2 vs placeboNCT01440101 | —Not reported |
| Free of 3-month confirmed disability progression (%) | —Not posted · NCT00027300 | —Not reported |
| New or enlarging T2 lesions | 0.3 vs 1.1−0.8 vs placeboNCT01440101 | —Not reported |
Annualised relapse rate
- natalizumab
- 0.5 vs 1.7−1.2 vs placeboNCT01440101
- Tyruko (natalizumab-sztn)
- —Not reported
Free of 3-month confirmed disability progression (%)
- natalizumab
- —Not posted · NCT00027300
- Tyruko (natalizumab-sztn)
- —Not reported
New or enlarging T2 lesions
- natalizumab
- 0.3 vs 1.1−0.8 vs placeboNCT01440101
- Tyruko (natalizumab-sztn)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Tyruko (natalizumab-sztn): no structured comparison results are available for Multiple Sclerosis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. natalizumab: 4 of 4 rows · Tyruko (natalizumab-sztn): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | natalizumab |
|---|---|
| Dropout rate | —IV Q4Wa NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 29 more results—IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W then SC Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —SC Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —SC Q6W then IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 0% NCT03046251 · Phase 4 · registry result, not featured evidence 12.1% NCT00871780 · Phase 4 · registry result, not featured evidence 20% NCT00536120 · Phase 4 · registry result, not featured evidence · combination —300 mg IV monthly NCT00306592 · Phase 3 · registry result, not featured evidence 2.1%Double-Blind Natalizumab NCT01440101 · Phase 2/3 · registry result, not featured evidence 16.7%Open Label Natalizumab NCT01440101 · Phase 2/3 · registry result, not featured evidence 59.8% NCT01416155 · Phase 2 · registry result, not featured evidence —300 mg IV every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg IV every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 4.4% NCT01071083 · Phase 2 · registry result, not featured evidence 18.6% NCT00516893 · Phase 2 · registry result, not featured evidence 25% NCT01071512 · Phase na · registry result, not featured evidence 66.7% NCT01455220 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —IV Q4Wa NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 29 more results—IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W then SC Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —SC Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —SC Q6W then IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 — NCT03046251 · Phase 4 · registry result, not featured evidence 2.7% NCT00871780 · Phase 4 · registry result, not featured evidence — NCT00536120 · Phase 4 · registry result, not featured evidence · combination —300 mg IV monthly NCT00306592 · Phase 3 · registry result, not featured evidence 0%Double-Blind Natalizumab NCT01440101 · Phase 2/3 · registry result, not featured evidence 16.7%Open Label Natalizumab NCT01440101 · Phase 2/3 · registry result, not featured evidence 8.2% NCT01416155 · Phase 2 · registry result, not featured evidence —300 mg IV every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg IV every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —300 mg SC every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence —150 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 0% NCT01071083 · Phase 2 · registry result, not featured evidence 2.7% NCT00516893 · Phase 2 · registry result, not featured evidence 5% NCT01071512 · Phase na · registry result, not featured evidence — NCT01455220 · Phase na · registry result, not featured evidence |
| Serious AEs | 6.9%IV Q4Wa NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 29 more results6.8%IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 1.5%IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —IV Q6W then SC Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 3%SC Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —SC Q6W then IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 1.9%IV Q6W NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 0% NCT03046251 · Phase 4 · registry result, not featured evidence 3.2% NCT00871780 · Phase 4 · registry result, not featured evidence 10% NCT00536120 · Phase 4 · registry result, not featured evidence · combination 5.6%300 mg IV monthly NCT00306592 · Phase 3 · registry result, not featured evidence 14.9%Double-Blind Natalizumab NCT01440101 · Phase 2/3 · registry result, not featured evidence 16.7%Open Label Natalizumab NCT01440101 · Phase 2/3 · registry result, not featured evidence 29.9% NCT01416155 · Phase 2 · registry result, not featured evidence 0%300 mg IV every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 13%300 mg IV every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 0%300 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 7.7%300 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 2.4%300 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 2.9%300 mg SC every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 5.7%300 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 8.9%300 mg SC every 4 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 2.4%150 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 6.3%150 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 8.5%150 mg IV every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence 2.6%150 mg SC every 12 weeks NCT01405820 · Phase 2 · registry result, not featured evidence — NCT01071083 · Phase 2 · registry result, not featured evidence 6.3% NCT00516893 · Phase 2 · registry result, not featured evidence 0% NCT01071512 · Phase na · registry result, not featured evidence 0% NCT01455220 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | IV Q4Wa nasopharyngitis 13% headache 9.3% urinary tract infection 7.7% NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 26 more resultsIV Q6W nasopharyngitis 10.8% headache 10.4% fatigue 10% NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 IV Q6W covid-19 20.6% headache 5.1% urinary tract infection 5.1% NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 SC Q6W covid-19 23.5% nasopharyngitis 9.8% arthralgia 6.1% NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 IV Q6W covid-19 12% urinary tract infection 3.8% fall 3.2% NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 ms relapse 50% NCT03046251 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 8.3% headache 6.4% NCT00871780 · Phase 4 · registry result, not featured evidence multiple sclerosis relapse 16.7% influenza 13.3% injection site erythrema 13.3% NCT00536120 · Phase 4 · registry result, not featured evidence · combination 300 mg IV monthly multiple sclerosis relapse 14.3% nasopharyngitis 12.9% upper respiratory tract infection 10.9% NCT00306592 · Phase 3 · registry result, not featured evidence nasopharyngitis 19.1% (placebo 29.8%) multiple sclerosis relapse 17% (placebo 36.2%) insomnia 6.4% (placebo 2.1%) NCT01440101 · Phase 2/3 · registry result, not featured evidence headache 25% (placebo 0%) nasopharyngitis 25% (placebo 29.8%) cystitis 16.7% (placebo 0%) NCT01440101 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 50.5% multiple sclerosis relapse 21.6% influenza 12.4% NCT01416155 · Phase 2 · registry result, not featured evidence 300 mg IV every 4 weeks nasopharyngitis 4.5% abdominal pain 0% arthralgia 0% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg IV every 4 weeks nasopharyngitis 24.1% multiple sclerosis relapse 14.8% urinary tract infection 14.8% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg IV every 12 weeks multiple sclerosis relapse 2.4% nasopharyngitis 2.4% abdominal pain 0% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg IV every 12 weeks multiple sclerosis relapse 25% nasopharyngitis 15.4% headache 13.5% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg SC every 12 weeks abdominal pain 0% arthralgia 0% back pain 0% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg SC every 4 weeks bronchitis 5.7% influenza 2.9% nasopharyngitis 2.9% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg SC every 12 weeks multiple sclerosis relapse 32.1% nasopharyngitis 17% headache 9.4% NCT01405820 · Phase 2 · registry result, not featured evidence 300 mg SC every 4 weeks headache 20% nasopharyngitis 17.8% fatigue 13.3% NCT01405820 · Phase 2 · registry result, not featured evidence 150 mg IV every 12 weeks multiple sclerosis relapse 7.1% influenza 2.4% abdominal pain 0% NCT01405820 · Phase 2 · registry result, not featured evidence 150 mg SC every 12 weeks influenza 9.4% multiple sclerosis relapse 6.3% nasopharyngitis 6.3% NCT01405820 · Phase 2 · registry result, not featured evidence 150 mg IV every 12 weeks multiple sclerosis relapse 25.5% influenza 17% nasopharyngitis 17% NCT01405820 · Phase 2 · registry result, not featured evidence 150 mg SC every 12 weeks multiple sclerosis relapse 13.2% headache 10.5% nasopharyngitis 10.5% NCT01405820 · Phase 2 · registry result, not featured evidence nasopharyngitis 24.4% (placebo 11.9%) headache 17.8% (placebo 7.1%) dizziness 6.7% (placebo 0%) NCT01071083 · Phase 2 · registry result, not featured evidence headache 19.6% fatigue 17.9% upper respiratory tract infection 17.9% NCT00516893 · Phase 2 · registry result, not featured evidence pruritis 5% NCT01071512 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
natalizumab
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 7 more results
show 7 more results
show 1 more result
show 1 more result
show 1 more result
+ 41 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: natalizumab's landscape · Tyruko (natalizumab-sztn)'s landscape